Molecular Aspects of Systemic Lupus Erythematosus

Benita Kurniawan; Francisca Veyta Ayu; Benny Mulyono Soegiharto; Elza Ibrahim Auerkari

doi:10.2991/978-94-6463-062-6_45

<Previous Article In Volume

Next Article In Volume>

Molecular Aspects of Systemic Lupus Erythematosus

Authors

Benita Kurniawan¹, Francisca Veyta Ayu², Benny Mulyono Soegiharto³, Elza Ibrahim Auerkari⁴^{, *}

¹Orthodontic Residency Program, Faculty of Dentistry, University of Indonesia, Salemba Raya Street, No. 4, Jakarta, 10430, Indonesia

²Master Program of Basic Dental Science - Forensic Odontology, Faculty of Dentistry, University of Indonesia, Kampus UI Salemba, Jakarta, 10430, Indonesia

³Departement of Orthodontic, Faculty of Dentistry, University of Indonesia, Salemba Raya Street, No. 4, Jakarta, 10430, Indonesia

⁴Department of Oral Biology-Division Forensic Odontology, Faculty of Dentistry, University of Indonesia, Salemba Raya Street, No. 4, Jakarta, 10430, Indonesia

^*Corresponding author. Email: elza.ibrahim@ui.ac.id

Corresponding Author

Elza Ibrahim Auerkari

Available Online 22 December 2022.

DOI: 10.2991/978-94-6463-062-6_45 How to use a DOI?
Keywords: Systemic lupus erythematosus; Autoimmune disease; Etiopathogenesis
Abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease caused by combined genetic and environmental factors that change the normal pathways of human immunity. SLE is potentially fatal and carries significant morbidity. The SLE patient can inherit multiple predisposing genes. T The identified SLE genes generally affect activation of autoimmune responses, resulting in aggregation of immune complexes. In order to help diagnose SLE, specific disease index system is used. In this index system, a minimum of four categories must be met to diagnose a patient with SLE. Steroid medication for immunomodulation can result in various side effects in long term use. Therefore, further research is important not only for deeper understanding of SLE etiopathogenesis, mechanisms and diagnosis, but also for optimized or improved therapies.
Open Access: Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume

Next Article In Volume>

Volume Title: Proceedings of the 4th International Conference on Life Sciences and Biotechnology (ICOLIB 2021)
Series: Advances in Biological Sciences Research
Publication Date: 22 December 2022
ISBN: 10.2991/978-94-6463-062-6_45
ISSN: 2468-5747
DOI: 10.2991/978-94-6463-062-6_45 How to use a DOI?
Open Access: Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

ris enw bib

TY  - CONF
AU  - Benita Kurniawan
AU  - Francisca Veyta Ayu
AU  - Benny Mulyono Soegiharto
AU  - Elza Ibrahim Auerkari
PY  - 2022
DA  - 2022/12/22
TI  - Molecular Aspects of Systemic Lupus Erythematosus
BT  - Proceedings of the 4th International Conference on Life Sciences and Biotechnology (ICOLIB 2021)
PB  - Atlantis Press
SP  - 451
EP  - 459
SN  - 2468-5747
UR  - https://doi.org/10.2991/978-94-6463-062-6_45
DO  - 10.2991/978-94-6463-062-6_45
ID  - Kurniawan2022
ER  -

download .riscopy to clipboard